Malnutrition-inflammation-atherosclerosis (MIA) syndrome components in hemodialysis and peritoneal dialysis patients

Renal Failure

Volumn 28, Issue 4, 2006, Pages 287-294

  Zeki Tonbul, H ^a   Demir, Murat ^b   Altintepe, Lütfullah ^a   Güney, Ibrahim ^a   Yeter, Ekrem ^a   Türk, Süleyman ^a   Yeksan, Mehdi ^a   Yildiz, Alaattin ^c  

^a SELCUK UNIVERSITY   (Turkey)

^b SULEYMAN DEMIREL UNIVERSITY   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Albumin; Atherosclerosis; Homocysteine; hs CRP; Malnutrition; MIA syndrome

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; FIBRINOGEN; HOMOCYSTEINE;

ADULT; ALBUMIN BLOOD LEVEL; ANTHROPOMETRY; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMODIALYSIS PATIENT; HUMAN; HYPOALBUMINEMIA; INFLAMMATION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; MEDICAL DECISION MAKING; MIA SYNDROME; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; TREATMENT PLANNING;

ADULT; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; FEMALE; HOMOCYSTEINE; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; MALE; MALNUTRITION; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; RENAL DIALYSIS; STATISTICS, NONPARAMETRIC; SYNDROME; TREATMENT OUTCOME;

EID: 33745544967     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220600583625     Document Type: Article

References (42)

1. Kalantar-Zadeh K, Kleiner M, Dunne E, Lee GH, Luft FC. A modified quantitative subjective global assessment of nutrition for dialysis patients. Nephrol. Dial. Transplant. 1999; 14:1732-1738.
2. Stenvinkel P, Heimburger O, Paultre F, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999;55:1899-1911.
3. Flanigan MJ, Frankenfield DL, Prowant BF, Bailie GR, Frederick PR, Rocco MV. Nutritional markers during peritoneal dialysis: data from the 1998 Peritoneal Dialysis Core Indicators Study. Perit. Dial. Int. 2001;21:345-354.
4. Zoccali C, Benedetto FA, Maas R, et al. CREED Investigators. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J. Am. Soc. Nephrol. 2002;13:490-496.
5. Nube MJ. The acute phase response in chronic haemodialysis patients: a marker of cardiovascular disease? Nephrol. Dial. Transplant. 2002;17:19-23.
6. Bergström J, Heimburger O, Lindholm B, Qureshi AR. Elevated serum C-reactive protein is a strong predictor of increased mortality and low serum albumin in hemodialysis (HD) patients. J. Am. Soc. Nephrol. 1995;6:573.
7. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999;55:648-658.
8. Iseki K, Tozawa M, Yoshi S, Fukiyama K. Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients. Nephrol. Dial. Transplant. 1999;14:1956-1960.
9. Noh H, Lee SW, Kang SW, et al. Serum C-reactive protein: a predictor of mortality in continuous ambulatory peritoneal dialysis patients. Perit. Dial. Int. 1998;18:387-394.
10. Haubitz M, Brunkhorst R. C-reactive protein and chronic Chlamydia pneumoniae infection - long-term predictors for cardiovascular disease and survival in patients on peritoneal dialysis. Nephrol. Dial. Transplant. 2001;16:809-815.
11. Stenvinkel P, Heimburger O, Lindholm B, Kaysen GA, Bergstrom J. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol. Dial. Transplant. 2000;15:953-960.
12. Stenvinkel P, Chung SH, Heimburger O, Lindholm B. Malnutrition, inflammation, and atherosclerosis in peritoneal dialysis patients. Perit. Dial. Int. 2001;21:157-162.
13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972;18:499-502.
14. Fermo I, Arcelloni C, Mazzola G, D'Angelo A, Paroni R. High-performance liquid chromatographic method for measuring total plasma homocysteine levels. J. Chromatogr. B Biomed. Sci. Appl. 1998;20:31-36.
15. Iseki K, Kawazoe N, Osawa A, Fukiyama K. Survival analysis of dialysis patients in Okinawa, Japan (1971-1990). Kidney Int. 1993;43:404-409.
16. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis. 1998;32:112-119.
17. Kimmel PL, Peterson RA, Weihs KL, et al. Psychosocial factors, behavioral compliance and survival in urban hemodialysis patients. Kidney Int. 1998;54:245-254.
18. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am. J. Kidney Dis. 1990;15:458-482.
19. Marckmann P. Nutritional status of patients on hemodialysis and peritoneal dialysis. Clin. Nephrol. 1988;29:75-78.
20. Bergstrom J, Lindholm B. Nutrition and adequacy of dialysis. How do hemodialysis and CAPD compare? Kidney Int. 1993;40:39-50.
21. Cianciaruso B, Brunori G, Kopple JD, et al. Cross-sectional comparison of malnutrition in continuous ambulatory peritoneal dialysis and hemodialysis patients. Am. J. Kidney Dis. 1995;26:475-486.
22. Qureshi AR, Alvestrand A, Danielsson A, et al. Factors predicting malnutrition in hemodialysis patients: a cross-sectional study. Kidney Int. 1998;53:773-782.
23. Kim H, Bologa R, Parker T, et al. Serum IL-6 as an indicator of survival outcome in CAPD patients (Abstract). J. Am. Soc. Nephrol. 1999;10:1248.
24. Yeun JY, Kaysen GA. Acute phase proteins and peritoneal dialysate albumin loss are the main determinants of serum albumin and peritoneal dialysis patients. Am. J. Kidney Dis. 1997;30:923-927.
25. Haubitz M, Brunkhorst R, Wrenger E, Froese P, Schulze M, Koch KM. Chronic induction of C-reactive protein by hemodialysis, but not by peritoneal dialysis therapy. Perit. Dial. Int. 1996;16:158-162.
26. Takahashi T, Kubota M, Nakamura T, Ebihara I, Koide H. Interleukin-6 gene expression in peripheral blood mononuclear cells from patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Ren. Fail. 2000;22:345-354.
27. Mitchell JRA, Schwartz JC. Relationship between arterial disease in different sites. A study of the aorta and coronary, carotid and iliac arteries. BMJ 1962;5288:1293-1301.
28. Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann. Intern. Med. 1998;128:262-269.
29. Zoccali C, Benedetto FA, Mallamaci F, et al. Inflammation is associated with carotid atherosclerosis in dialysis patients. Creed investigators. Cardiovascular risk extended evaluation in dialysis patients. J. Hypertens. 2000;18:1207-1213.
30. Heinecke JW, Rosen H, Suzuki LA, Chait A. The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J. Boil. Chem. 1987;262:10098-10103.
31. Tsai JC, Perrella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc. Natl Acad. Sci. USA 1994;91:6369-6373.
32. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J. Clin. Invest. 1991;88:1906-1914.
33. Rigatto C, Parfrey PS. Homocysteine and cardiovascular risk in dialysis patients. Perit. Dial. Int. 2000;20:167-168.
34. Yeun JY, Kaysen GA. C-reactive protein, oxidative stress, homocysteine, and troponin as inflammatory and metabolic predictors of atherosclerosis in ESRD. Curr. Opin. Nephrol. Hypertens. 2000;9:621-630.
35. Lim PS, Hung WR, Wei YH. Polymorphism in methylenetetrahydrofolate reductase gene: its impact on plasma homocysteine levels and carotid atherosclerosis in ESRD patients receiving hemodialysis. Nephron. 2001;87:249-256.
36. Lentz SR. Homocysteine and vascular dysfunction. Life Sci. 1997;61:1205-1215.
37. Moustapha A, Gupta A, Robinson K, et al. Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis. Kidney Int. 1999;55:1470-1475.
38. Mallamaci F, Zoccali C, Tripepi G, et al. Creed investigators. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int. 2002;61:609-614.
39. Libella C, Villa G, Pirrelli S, et al. Homocysteine plasma levels correlate with intimal carotid artery thickness in hemodialysis patients. Nephrol. Dial. Transplant. 2001; 16:2444-2445.
40. Suliman ME, Stenvinkel P, Heimburger O, Barany P, Lindholm B, Bergstrom J. Plasma sulfur amino acids in relation to cardiovascular disease, nutritional status, and diabetes mellitus in patients with chronic renal failure at start of dialysis therapy. Am. J. Kidney Dis. 2002;40:480-488.
41. Kalantar-Zadeh K, Block G, Humphreys MH, McAllister CJ, Kopple JD. A low, rather than a high total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J. Am. Soc. Nephrol. 2004;15:442-453.
42. Suliman ME, Qureshi AR, Barany P, et al, Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int. 2000;57(4):1727-1735.